Literature DB >> 33277808

Retrospective study of nail telemedicine visits during the COVID-19 pandemic.

Michelle J Chang1, Claire R Stewart2, Shari R Lipner2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33277808      PMCID: PMC7883270          DOI: 10.1111/dth.14630

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   3.858


× No keyword cloud information.
Dear Editor The COVID‐19 pandemic has resulted in rapid adoption of telemedicine, with recent teledermatology interest and recommendations. Nail telemedicine has not been explored and guidelines are lacking. Our study objectives were to analyze characteristics of nail teledermatology visits and provide recommendations for virtual nail visits. Following Weill Cornell Institutional Review Board approval (Protocol #20‐03021691‐01), all virtual nail visits (16 March 2020 to 5 May 2020) seen by a nail specialist (SRL) were queried from EPIC. Analyses were performed using t‐tests for continuous variables and chi‐squared tests for categorical variables, with significance set at P < .05. There were 107 total visits, representing 96 patients during the study period. Demographics and clinical characteristics of nail televisits are shown in Table 1. The average age was 46.1 years, with 68% females. Longitudinal melanonychia was the most frequent new complaint (8/46 patients, 17%), with in‐person follow‐up recommended for 7/8 patients. Onychomycosis was the favored diagnosis for 7/46 (15%) new visits, with 6/7 requiring an in‐person visit for mycological confirmation. Onychomycosis (18/50, 36%) and nail psoriasis (9/50, 18%) were the most common diagnoses for virtual follow‐up visits. In‐person follow‐ups were recommended for 57% of new nail conditions. New vs follow‐up virtual visits were 14 times more likely to necessitate in‐person visits (P < .01). Nail patients were recommended to come for office visits for clinical examination/dermoscopy (39%), nail clippings (32%), biopsies (18%), and other procedures (11%). For all visits, systemic medications were five times more likely to be re‐ordered/continued vs started (P < .01).
TABLE 1

Demographics and clinical characteristics of virtual nail visits

New complaint (N = 46)Follow‐up (N = 50)
Age44.4 (12‐82)48.6 (9‐77)
Female (%)7058
Single (%)3442
Insurance (%)
Private Insurance8578
Medicare1320
Self‐pay22
Ethnicity (%)
White4636
Black44
Asian42
Other94
Declined3754
Hispanic/Latino22
Not Hispanic/Latino4638
Unknown42
Declined4858
Distance to clinic (Miles)10.312.8
Involvement (%)
Fingers4836
Toes3946
Both1318
Referrals (%)
Dermatology29
Internal medicine15
Other4
No referral52
Avg. time from last in‐office visit (days)77
In‐person follow‐up (%)544
Reasons for in person follow‐up (%)
Clinical examination/dermoscopy420
Nail sampling (clipping for histopathology, scraping for KOH, culture, PCR)350
Nail biopsy190
Treatment (intralesional nail matrix injections, incision and drainage, biologics)4100
Medications
Average no. of new medications started0.390.22
Topical (%)9492
Systemic (%)68
Average no. of medications continued/reordered0.62
Topical (%)51
Systemic (%)49
Average no. of medications stopped0.06
Demographics and clinical characteristics of virtual nail visits More than half of new virtual visits could not be managed by telemedicine and required subsequent in‐person visits (Table 2). This subgroup of patients fell into distinct diagnostic categories. For example, patients with suspected onychomycosis necessitated confirmatory testing. Telemedicine was appropriate for onychomycosis follow‐ups, including examination for clinical improvement, medication counseling, monitoring adverse events, interval laboratory monitoring in high‐risk populations, and education on preventing recurrence. In the vast majority of cases, longitudinal melanonychia, both new and follow‐up, particularly involving a single digit, required an in‐person visit for monitoring, including high quality photography, precise measurements, and dermoscopy. Subungual hematomas and body‐focused repetitive behaviors, including onychophagia and onychotillomania, typically had consistent clinical features and could be managed by telemedicine.
TABLE 2

Number of patients with recommendations for in‐person visits after new and follow‐up virtual visits

DiagnosisNew complaint no. a In‐person follow‐up recommended no. (%)Follow‐up no. a In‐person follow‐up recommended no. (%)
Beau's line2020
Brittle nails3000
Pseudomonas nail infection4020
Half and half nails1000
Lichen planus11 (100)10
Longitudinal melanonychia87 (88) c 20
Myxoid cyst22 (100)00
Nail psoriasis31 (33)92 (22)
Unspecified66 (100)10
Onychocryptosis2010
Onychomatricoma11(100)00
Onychomycosis76 (86) b 180
Onychopapilloma11 (100)20
Onychophagia/Onychotillomia/Habit Tic4040
Chronic paronychia3040
Retronychia32 (67)70
Subungual exostosis11 (100)00
Subungual hematoma5000
Trauma5010

Number of diagnoses exceeds total number of patients because some patients had more than one diagnosis.

Six of seven new patient complaints with diagnoses of onychomycosis required an in‐person follow‐up visit for mycological confirmation. The patient that did not require in‐person follow up had prior mycological confirmation.

Seven of eight new patient complaints of longitudinal melanonychia required an in‐person follow‐up visit. The patient that did not require in‐person follow up had gray‐brown bands involving multiple nails.

Number of patients with recommendations for in‐person visits after new and follow‐up virtual visits Number of diagnoses exceeds total number of patients because some patients had more than one diagnosis. Six of seven new patient complaints with diagnoses of onychomycosis required an in‐person follow‐up visit for mycological confirmation. The patient that did not require in‐person follow up had prior mycological confirmation. Seven of eight new patient complaints of longitudinal melanonychia required an in‐person follow‐up visit. The patient that did not require in‐person follow up had gray‐brown bands involving multiple nails. To triage nail patients for in‐person vs virtual visits most efficiently, effectively, and economically, prescreening using photographs by attending or resident dermatologists should be considered. We acknowledge that this approach requires additional physician time commitment, which may not be feasible in all practice settings. Artificial intelligence should be developed for this purpose to decrease health care costs and improve patient care. Limitations include single‐center, retrospective design, data from one dermatologist, and sample size. Since only one patient had an in‐person follow‐up during the study period, outcomes could not be analyzed. In sum, telemedicine can be utilized to manage patients with previously diagnosed nail diseases and diagnose some new nail conditions. Patients with longitudinal melanonychia and suspected onychomycosis should be scheduled exclusively for in‐person visits. Further research in nail telemedicine is needed to analyze patient outcomes to establish more rigorous guidelines.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.
  5 in total

Review 1.  Onychotillomania: Diagnosis and Management.

Authors:  Pierre Halteh; Richard K Scher; Shari R Lipner
Journal:  Am J Clin Dermatol       Date:  2017-12       Impact factor: 7.403

2.  Performance of a deep neural network in teledermatology: a single-centre prospective diagnostic study.

Authors:  C Muñoz-López; C Ramírez-Cornejo; M A Marchetti; S S Han; P Del Barrio-Díaz; A Jaque; P Uribe; D Majerson; M Curi; C Del Puerto; F Reyes-Baraona; R Meza-Romero; J Parra-Cares; P Araneda-Ortega; M Guzmán; R Millán-Apablaza; M Nuñez-Mora; K Liopyris; C Vera-Kellet; C Navarrete-Dechent
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-11-22       Impact factor: 6.166

3.  Considerations for management of longitudinal melanonychia during the coronavirus disease 2019 (COVID-19) pandemic: An international perspective.

Authors:  Shari R Lipner; Matilde Iorizzo; Nathaniel Jellinek; Bianca Maria Piraccini; Richard K Scher
Journal:  J Am Acad Dermatol       Date:  2020-05-13       Impact factor: 11.527

Review 4.  Recommendations for diagnosis and treatment of onychomycosis during the COVID-19 pandemic.

Authors:  Shari R Lipner; Jose W Ricardo
Journal:  Dermatol Ther       Date:  2020-06-25       Impact factor: 3.858

Review 5.  Teledermatology: current indications and considerations for future use.

Authors:  Jacob Beer; Edward Hadeler; Alejo Calume; Howard Gitlow; Keyvan Nouri
Journal:  Arch Dermatol Res       Date:  2020-10-19       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.